Ear­ly da­ta on Takeda's dengue vac­cine is promis­ing, but wait for the full dataset

Take­da’s an­swer to Sanofi’s con­tro­ver­sial dengue vac­cine is here. The Japan­ese drug­mak­er, which is hop­ing to avert the chal­lenges faced by its French ri­val to de­vel­op a prod­uct for the mos­qui­to-borne dis­ease, broke out the num­bers from the first tranche of its piv­otal tri­al on Wednes­day.

The place­bo-con­trolled tri­al, called TIDES, is test­ing the im­pact of two dos­es of the vac­cine — TAK-003 — in pre­vent­ing dengue fever, trig­gered by any of the four vi­ral strains, in more than 19,000 pa­tients aged four to 16 years in parts of Latin Amer­i­ca and Asia where the dis­ease is en­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER